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Summary
Background Limited access to essential medicines is a global problem. Improving availability and aﬀ ordability of 
essential medicines is a key objective of the National Essential Medicine Policy (NEMP) in China. In its initial 
implementation in 2009, the NEMP targeted primary hospitals with policies designed to increase availability of 
essential medicines and reduce patients’ economic burden from purchasing medicines. We assessed medicine 
availability and price during the early years of the health reform in Shaanxi Province in underdeveloped western 
China.
Methods We undertook two public (hospitals) and private (pharmacy) sector surveys of prices and availability of 
medicines, in September, 2010 and April, 2012, by a standard methodology developed by WHO and Health Action 
International. We measured medicine availability in outlets at the time of the surveys and inﬂ ation-adjusted median unit 
prices (MUPs), taking 2010 as the base year. We used general estimating equations to calculate the signiﬁ cance of 
diﬀ erences in availability from 2010 to 2012 and the Wilcoxon signed rank test to calculate the signiﬁ cance of diﬀ erences 
in adjusted median prices. 
Findings We collected data from 50 public sector hospitals and 36 private sector retail pharmacies in 2010 and 72 public 
hospitals and 72 retail pharmacies in 2012. Mean availability of surveyed medicines was low in both the public and 
private sectors; availability of many essential medicines decreased from 2010 to 2012, particularly in primary hospitals 
(from 27·4% to 22·3% for lowest priced generics; p<0·0001). The MUPs of originator brands and their generic 
equivalents decreased signiﬁ cantly from 2010 to 2012 in primary hospitals in comparison with secondary and tertiary 
hospitals. In the public sector, the median adjusted patient price was signiﬁ cantly lower in 2012 than in 2010 for 
16 originator brands (diﬀ erence –11·7%; p=0·0019) and 29 lowest-priced generics (–5·2%; p=0·0015); the median 
government procurement price for originator brands also decreased signiﬁ cantly (–10·9%; p=0·0004), whereas the 
decrease in median procurement price for lowest-priced generics was not signiﬁ cant (–4·9%; p=0·17). In the private 
sector, the median percentage decrease in price between 2010 and 2012 for 38 lowest-priced generics was 4·7% 
(IQR 6·3–13·2), compared with 7·9% (4·9–13·9) for 16 originator brands.
Interpretation Although inﬂ ation-adjusted medicine prices were numerically lower, there were concerning decreases 
in availability of lowest-priced generic medicines in both the public and private sectors in 2012 from already low 
availability in 2010. A long-term, stable, and consistent information system is needed to monitor eﬀ ects of further 
implementation of the Chinese Essential Medicine Policy.
Funding The National Natural Science Fund (71103141/G0308), the China Medical Board Faculty Development 
Awards, the Fundamental Research Funds for the Central Universities (2011jdhz62), the Shaanxi Provincial Social 
Science Fund (10E066), and the Harvard Medical School Pharmaceutical Policy Research Fellowship. 
Introduction
Access to low-cost essential medicines
Equitable access to essential medicines is part of the 
fulﬁ lment of the right to the highest attainable standard 
of health.1 However, high medicine prices make 
medicines unaﬀ ordable for many people.2
After China’s economic reform and opening up the 
economy to the outside world in the late 1970s, access of 
most Chinese to basic health care did not keep pace with 
economic growth.3 Health services became unaﬀ ordable 
and inaccessible for disadvantaged populations,4 
disparities between regions increased, and out-of-pocket 
health expenditures grew.5 In 2009, Chinese national 
health-care expenditures amounted to US$240 billion, or 
about 5% of the gross domestic product (GDP), and 
more than 40% of this expenditure was on medications,5 
one of the highest proportions in the world.6,7 The high 
cost of medical products continues to be a major obstacle 
to access to health care in China.8,9
In response to these issues, the Chinese Government 
announced in 2009 a systematic plan to achieve universal 
access to health care by 2020; one of the key pillars was 
the establishment of a National Essential Medicines 
Policy (NEMP) to ensure drug safety, quality, supply, and 
aﬀ ordability.10,11 The NEMP included speciﬁ c policies 
targeting medicine production, pricing, procurement, 
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prescribing, and reimbursement. A key policy element of 
the NEMP is a zero mark-up policy under which essential 
medicines are sold to patients for procurement price plus 
a ﬁ xed distribution cost, with no proﬁ t to the health 
facility for the sale. The central government has also 
instructed provincial governments to organise public 
bidding for essential medicines to achieve the lowest 
possible procurement prices.
Essential medicines system in Shaanxi Province, 
western China
Shaanxi Province has a population of nearly 38 million 
people and has 11 cities, with Xi’an the capital. The total 
provincial GDP was US$196·7 billion in 2011, ranking in 
the middle to lower level in China.12 Shaanxi Province is 
broadly representative of the typical health and health 
system status of the 12 western provinces of China. As 
such, in 2012, the Ministry of Health of China and WHO 
selected Shaanxi Province as one of three pilot regions 
for the Western Area Health Initiative, which will be 
implemented from 2012 to 2015 to address key health 
issues in western China.13
The NEMP has been implemented in stages in Shaanxi 
Province.14 In September 2010, the Shaanxi Provincial 
Essential Medicines List (EML) was issued to supplement 
the 2009 National EML (NEML)15 and to meet local 
needs.16,17 The provincial Health Department emphasised 
that all primary health-care institutions must acquire and 
use essential medicines18 and set speciﬁ c use targets: in 
secondary and tertiary hospitals, at least 40% and 30%, 
respectively, of all medicines used should be on the EML, 
and the inpatient and outpatient sales of essential 
medicines should be no less than 30% and 20% of total 
sales, respectively.19 In the private sector, improvement of 
the use and supply of essential medicines was encouraged, 
but there were no mandatory requirements. Patients can 
purchase prescribed essential medicines in private retail 
pharmacies, and in Shaanxi Province the insurance 
reimbursement of essential medicines is required to be 
5–10% higher than that of non-essential medicines.20
The zero mark-up policy was implemented in primary 
hospitals (including urban community health-care 
centres, rural township hospitals, and village clinics) in 
two cities (Yulin and Baoji) in June, 2009; primary 
hospitals in Xianyang, Shangluo, and Tongchuan followed 
in December, 2009, and primary hospitals in the 
remaining ﬁ ve cities implemented the policy in November, 
2010. By the end of 2011, all 234 community health-care 
centres and 1725 township hospitals in 107 districts and 
counties of Shaanxi Province had implemented the zero 
mark-up policy. The Shaanxi Provincial Government 
aimed to expand the policy to county-level public hospitals 
starting in January, 2012,21 with later extension to 
secondary and tertiary hospitals (no date set).10
A provincial coordinating centre in Xi’an is in charge of 
“uniﬁ ed bidding, uniﬁ ed distribution, and uniﬁ ed 
pricing” of essential medicines (three uniﬁ cation 
policy).22 In February, 2010, the coordinating centre 
announced the bidding results for 1034 products from 
367 drug suppliers that won the tender;23 the Shaanxi 
bidding prices were a mean of 46·1% lower than national 
reference prices.23 Distribution costs are set at 5% of drug 
prices.22 The replacement of drug sales revenues by the 
zero mark-up policy in primary hospitals has led to a 
serious drop in income for hospitals.24 Direct subsidies 
by central, provincial, and municipal governments, 
higher user fees, and higher insurance payments for 
medical services are intended to oﬀ set revenue losses.
Despite these policy measures, to what extent access 
to aﬀ ordable essential medicines has been improved in 
western China is unclear. A small number of studies 
have attempted to assess the eﬀ ects of the NEMP,24–34 but 
these were based on non-independent authority reports 
or limited qualitative descriptions. To address this 
2010 survey 2012 survey
Public hospitals Private 
pharmacies
Public hospitals Private 
pharmacies
Primary Secondary Tertiary Total Primary Secondary Tertiary Total
High-income districts*
Xi’an 2 (4) 2 (3) 1 (1) 5 (8) 5 (7) 3 (6) 2 (4) 1 (2) 6 (12) 6 (12)
Yulin 2 (4) 2 (3) 1 (1) 5 (8) 5 (8) 3 (6) 2 (4) 1 (2) 6 (12) 6 (12)
Middle-income districts*
Xianyang 2 (4) 2 (3) 1 (1) 5 (8) 5 (5) 3 (6) 2 (4) 1 (2) 6 (12) 6 (12)
Baoji 2 (4) 2 (4) 1 (1) 5 (9) 5 (5) 3 (6) 2 (4) 1 (2) 6 (12) 6 (12)
Low-income districts*
Weinan 2 (4) 2 (4) 1 (1) 5 (9) 5 (6) 3 (6) 2 (4) 1 (2) 6 (12) 6 (12)
Shangluo 2 (4) 2 (3) 1 (1) 5 (8) 5 (5) 3 (6) 2 (4) 1 (2) 6 (12) 6 (12)
Total 12 (24) 12 (20) 6 (6) 30 (50) 30 (36) 18 (36) 12 (24) 6 (12) 36 (72) 36 (72)
Data are planned (actually surveyed) facilities. According to the WHO and Health Action International survey method, an additional facility is added to the sample if fewer 
than 50% of medicines were available on the day of the survey in a given facility. *By GDP per person in 2010.
Table 1: Planned and actual number of sample facilities 
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scarcity of empirical knowledge, we undertook two 
cross-sectional surveys to analyse medicine prices, 
availability, and aﬀ ordability in Shaanxi Province during 
the early years of implementation of the NEMP. We 
hypothesised that the NEMP would lead to a decrease in 
prices of essential medicines and a gradual increase in 
NEML WHO/HAI 
list
Procure ment 
list*
Public sector availability (%) Private sector availability (%)
LPG OB LPG OB
2010 2012 2010 2012 2010 2012 2010 2012
Medicine
Aciclovir Yes S Yes 0·0% 2·8% 0·0% 0·0% 27·8% 27·8% 0·0% 0·0%
Albendazole Yes R Yes 10·0% 9·7% 32·0% 25·0% 8·3% 5·6% 94·4% 68·1%
Aminophylline Yes S Yes 78·0% 66·7% 0·0% 0·0% 75·0% 65·3% 0·0% 0·0%
Amitriptyline Yes G Yes 16·0% 12·5% 0·0% 0·0% 22·2% 11·1% 0·0% 0·0%
Amlodipine No R No 22·0% 20·8% 32·0% 37·5% 41·7% 38·9% 58·3% 63·9%
Amoxicillin Yes G Yes 16·0% 26·4% 0·0% 0·0% 77·8% 83·3% 2·8% 0·0%
Atenolol Yes G No 0·0% 0·0% 0·0% 0·0% 0·0% 0·0% 0·0% 1·4%
Atorvastatin No R No 2·0% 2·8% 26·0% 37·5% 5·6% 8·3% 63·9% 61·1%
Azithromycin Yes S Yes 52·0% 47·2% 6·0% 4·2% 88·9% 79·2% 8·3% 12·5%
Beclometasone No R No 0·0% 0·0% 14·0% 9·7% 0·0% 0·0% 22·2% 15·3%
Captopril Yes G Yes 82·0% 75·0% 0·0% 0·0% 100·0% 91·7% 0·0% 0·0%
Cefalexin Yes R Yes 18·0% 11·1% 0·0% 0·0% 50·0% 30·6% 0·0% 0·0%
Cefradine No S No 4·0% 2·8% 0·0% 0·0% 19·4% 9·7% 0·0% 0·0%
Ceftriaxone Yes G Yes 76·0% 52·8% 16·0% 26·4% 69·4% 41·7% 2·8% 2·8%
Ciproﬂ oxacin Yes G No 0·0% 1·4% 0·0% 0·0% 11·1% 9·7% 0·0% 0·0%
Co-trimoxazole Yes S Yes 62·0% 27·8% 0·0% 1·4% 83·3% 68·1% 0·0% 1·4%
Diazepam Yes G No 4·0% 0·0% 0·0% 0·0% 0·0% 0·0% 0·0% 0·0%
Diclofenac Yes G Yes 20·0% 1·4% 0·0% 1·4% 27·8% 23·6% 0·0% 8·3%
Digoxin Yes S Yes 68·0% 59·7% 0·0% 1·4% 72·2% 65·3% 2·8% 0·0%
Enalapril Yes R Yes 52·0% 56·9% 0·0% 0·0% 94·4% 87·5% 0·0% 0·0%
Erythromycin Yes S Yes 4·0% 0·0% 0·0% 0·0% 2·8% 11·1% 0·0% 0·0%
Fluconazole Yes S Yes 4·0% 1·4% 0·0% 0·0% 19·4% 22·2% 5·6% 0·0%
Fluoxetine No R No 4·0% 1·4% 8·0% 5·6% 11·1% 2·8% 19·4% 22·2%
Glibenclamide Yes G No 0·0% 0·0% 0·0% 0·0% 5·6% 2·8% 0·0% 0·0%
Gliclazide No R No 28·0% 30·6% 34·0% 19·4% 52·8% 58·3% 61·1% 41·7%
Hydrochlorothiazide Yes R Yes 70·0% 62·5% 0·0% 0·0% 80·6% 63·9% 0·0% 0·0%
Ibuprofen Yes R No 0·0% 0·0% 0·0% 0·0% 2·8% 4·2% 0·0% 1·4%
Ketoconazole No S No 0·0% 0·0% 30·0% 18·1% 0·0% 1·4% 75·0% 56·9%
Lisinopril No S No 2·0% 0·0% 0·0% 0·0% 11·1% 9·7% 2·8% 0·0%
Loratadine No S Yes 18·0% 19·4% 18·0% 9·7% 44·4% 62·5% 91·7% 47·2%
Losartan No S No 6·0% 5·6% 18·0% 19·4% 11·1% 12·5% 33·3% 27·8%
Lovastatin No S No 14·0% 15·3% 0·0% 0·0% 50·0% 50·0% 0·0% 0·0%
Metformin Yes R Yes 6·0% 2·8% 18·0% 20·8% 41·7% 25·0% 50·0% 40·3%
Metronidazole Yes R Yes 98·0% 79·2% 0·0% 1·4% 94·4% 63·9% 0·0% 0·0%
Miconazole nitrate Yes S Yes 4·0% 6·9% 84·0% 65·3% 22·2% 6·9% 94·4% 83·3%
Nifedipine retard No R No 32·0% 25·0% 0·0% 2·8% 61·1% 50·0% 19·4% 23·6%
Oﬂ oxacin No S No 0·0% 0·0% 0·0% 0·0% 8·3% 4·2% 0·0% 0·0%
Omeprazole Yes G Yes 80·0% 63·9% 20·0% 25·0% 86·1% 80·6% 36·1% 41·7%
Paracetamol Yes S Yes 6·0% 2·8% 0·0% 1·4% 13·9% 8·3% 2·8% 2·8%
Ranitidine Yes R Yes 50·0% 40·3% 0·0% 0·0% 91·7% 75·0% 0·0% 0·0%
Rifampicin Yes S Yes 44·0% 30·6% 0·0% 1·4% 83·3% 51·4% 0·0% 0·0%
Salbutamol Yes G Yes 20·0% 4·2% 30·0% 26·4% 61·1% 18·1% 30·6% 34·7%
Simvastatin Yes G No 16·0% 9·7% 24·0% 23·6% 50·0% 58·3% 50·0% 41·7%
Sodium valproate Yes R Yes 32·0% 22·2% 0·0% 0·0% 69·4% 61·1% 2·8% 1·4%
(Continues on next page)
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availability of medicine in health-care institutions, 
particularly in primary hospitals.
Methods
Study design
We undertook two cross-sectional surveys of medicine 
availability and prices in Shaanxi Province in September, 
2010, and April, 2012, with a standard methodology 
developed by WHO and Health Action International 
(WHO/HAI),35 which has been used in previous studies 
in eastern and central China.36–38 In the present study, we 
focused on changes in medicine availability and price 
from 2010 to 2012; the reports of the complete survey are 
available from WHO/HAI.39,40
All institutions agreed to participate in the study. 
Shaanxi Provincial Department of Health and Shaanxi 
Food and Drug Administration approved the study before 
data collection. Ethical approval was obtained from the 
Research Ethics Committee at Xi’an Jiaotong University 
Health Science Centre.
Procedures
We selected health facilities systematically for both 
surveys. We ﬁ rst classiﬁ ed the ten areas in Shaanxi 
Province into three income strata (high, middle, and 
low)  according to GDP per capita in 2010. The highest 
and lowest income areas in each stratum (Xi’an and 
Yulin, Xianyang and Baoji, and Shangluo and Weinan, 
respectively) were surveyed in both years. In each 
survey area, ﬁ ve public sector (hospital) medicine 
outlets were selected at random from those within a 4 h 
drive from the main hospital in 2010, whereas six were 
selected in 2012. A private sector pharmacy near each 
selected public health facility was also surveyed. Back-
up outlets were selected in case availability of the 
surveyed medicines was less than 50% at a given outlet, 
a feature of the WHO/HAI survey design. As a result, 
the actual number of outlets surveyed was larger than 
the planned sample.
44 medicines were surveyed in both years: 27 from the 
WHO/HAI core global and regional lists (representing 
medicines for common acute and chronic disorders) 
and 17 locally selected supplementary medicines chosen 
for their local importance and disease burden,41,42 with 
input from an advisory committee of practising 
pharmacists, academics, and experts from the Shaanxi 
Provincial Center for Medicine Procurement (Xi’an, 
Shaanxi Province). Of the 44 medicines surveyed, 
31 were on the NEML and 26 were on the 2010–12 
Shaanxi provincial medicines procurement list. 
23 medicines treat acute disorders, whereas 21 treat 
chronic disorders (appendix).
Data collection and entry are described in detail 
elsewhere.39,40 Brieﬂ y, data were collected during on-site 
visits to each public and private facility. As required by 
the WHO/HAI survey method, data were collected on 
the availability and price of both the originator brand 
(OB) and the lowest-priced generic (LPG) equivalent of 
every medicine. Prices charged to patients were collected 
in both public and private medicine outlets for all 
medicines found in the outlet on the day of the survey. 
Procurement prices for the same products were obtained 
from the Shaanxi Provincial Center for Medicine 
Procurement website43 or, if not listed, at individual 
medicine outlets.
Statistical analysis
Availability is reported as the percentage of facilities in 
which each product was found on the day of data 
collection. Medicine prices are expressed as median unit 
prices (MUPs) in RMB (yuan; ¥). Unit price refers to the 
price per individual tablet, capsule, millilitre (eg, for 
injections or liquids), gram (for creams), or dose (for 
inhalers).35 We adjusted 2012 unit prices to 2010 prices by 
deﬂ ating them by 5·186%.44 To be included in analyses, 
we required at least two procurement prices or at least 
two public or private sector prices charged to patients for 
each medicine. The change in prices over 2 years was 
NEML WHO/HAI 
list
Procure ment 
list*
Public sector availability (%) Private sector availability (%)
LPG OB LPG OB
2010 2012 2010 2012 2010 2012 2010 2012
(Continued from previous page)
Mean availability
All medicines 25·5% 20·5% 9·3% 8·7% 42·0% 35·3% 18·9% 15·9%
Medicines on Shaanxi 
provincial procurement 
list
37·9% 30·2% 8·6% 8·1% 58·0% 47·3% 16·3% 13·2%
Medicines not listed on 
Shaanxi provincial 
procurement list
7·4% 6·4% 10·3% 9·6% 19·0% 17·8% 22·5% 19·8%
cap=capsule. G=global core list. HAI=Health Action International. NEML=2009 National Essential Medicines List. LPG=lowest-price generic. OB=originator brand. R=regional 
core list. S=supplementary list. tab=tablet. *2010–12 Shaanxi provincial medicines procurement list. 
Table 2: Availability of 44 medicines in public sector hospitals and private retail pharmacies
See Online for appendix
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computed as the median of the product-speciﬁ c 
percentage changes in price from 2010 to 2012.
Our primary analysis compared the availability and 
prices of products found in both years in all facilities. 
We compared availability and prices in the subset of 
public sector facilities that were included in the surveys 
in both years in a sensitivity analysis.45 We also compared 
mean availability and MUPs between groups of 
medicines (OBs and LPGs; medicines for acute and 
chronic disorders; medicines on the provincial 
procurement list and not; and NEML and non-NEML 
medicines), across years, and across diﬀ erent levels of 
public facilities (primary hospital versus secondary and 
tertiary hospitals).
We used generalised estimating equations to test 
diﬀ erences in availability of all medicines included in 
both surveys, with facility speciﬁ ed as a random eﬀ ect. 
We used the Wilcoxon signed rank test to identify 
whether the reductions or increases in adjusted median 
prices between 2010 and 2012 were signiﬁ cant. To adjust 
for multiple comparisons, we classed p<0·01 as a 
signiﬁ cant diﬀ erence in all statistical testing.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of the report, or the decision to submit the manuscript. 
All authors had full access to all the data in the study and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
We collected data from 50 public sector hospitals and 
36 private sector retail pharmacies in 2010 and 72 public 
hospitals and 72 retail pharmacies in 2012 (table 1); data 
from 26 public hospitals surveyed in both years were 
used for the sensitivity analysis (appendix).
In the public sector, availability of surveyed medicines 
was poor in both years. Of the 44 medicines surveyed, 
numbers of medicines found in more than 10% of public 
facilities in 2010 and 2012 were 24 and 21 for LPGs and 
14 and 12 for OBs, respectively; in private facilities, 
corresponding numbers were 34 and 29 for LPGs and 15 
and 16 for OBs. Additionally, there was a signiﬁ cant 
decrease in mean availability of LPGs in 2012 (20·5%) 
Figure 1: Change in availability of 44 medicines in the public sector from 2010 to 2012
LPG=lowest-priced generic. NEML=2009 National Essential Medicines List. OB=original brand. PL=2010–12 Shaanxi provincial medicines procurement list.
0 5 10 15 20 25 30 35 40 45 50 55
 
Tertiary hospital
LPG-PL
LPG-non-PL
OB-PL
OB-non-PL
LPG-NEML
LPG-non-NEML
OB-NEML
OB-non-NEML
Secondary hospital
LPG-PL
LPG-non-PL
OB-PL
OB-Non-PL
LPG-NEML
LPG-non-NEML
OB-NEML
OB-non-NEML
Primary hospital
LPG-PL
LPG-non-PL
OB-PL
OB-non-PL
LPG-NEML
LPG-non-NEML
OB-NEML
OB-non-NEML
Decrease Increase
Change (%)
Articles
e232 www.thelancet.com/lancetgh   Vol 1   October 2013
compared with 2010 (25·5%; p<0·0001), but no signiﬁ cant 
change in mean availability of OBs (8·7% vs 9·3%, 
respectively; p=0·40). In the private sector, availability of 
surveyed medicines in 2012 and 2010 (35·3% vs 42·0% 
for LPGs, p=0·0003; 15·9% vs 18·9% for OBs, p=0·012, 
respectively) was higher than in the public sector, but still 
very low (table 2). The mean availability of 21 LPGs used 
for chronic disorders (public 26·2% in 2010 vs 22·6% in 
2012; private 43·7% vs 37·2%) was numerically higher in 
both sectors than for the 23 medicines for acute disorders 
(24·8% vs 18·6%; 24·8% vs 18·4%, respectively). 
Availability was numerically lower in all cases in 2012 
compared with 2010, but only the reduction in LPG 
availability for chronic medicines in the private sector was 
statistically signiﬁ cant (p=0·0016). Availability of OBs was 
less than 10% in both sectors in both years, with no 
signiﬁ cant changes.
For individual medicines, availability varied by type of 
medicine and sector (table 2). In the public sector, 11 and 
eight LPG medicines had at least 50% availability in 2010 
and 2012, and 20 and 18 in the private sector, respectively. 
For OB medicines, one medicine had over 50% 
availability in each year in the public sector; in the private 
sector, nine products had at least 50% availability in 2010 
which decreased to ﬁ ve in 2012. No public outlet carried 
any of the assessed formulations of four medicines 
(atenolol, glibenclamide, ibuprofen, and oﬂ oxacin). 
Three LPGs (atenolol, beclometasone, and diazepam) 
were not found in any private outlet.
In primary hospitals, the main target of the NEMP, 
mean availability of LPGs decreased signiﬁ cantly from 
27·4% in 2010 to 22·3% in 2012 for medicines included 
in the NEML (p<0.0001), whereas availability of medicines 
not included in the NEML did not change (6·7% in 2012 
vs 6·8% in 2010; p=048; ﬁ gure 1). Mean availability of 
LPGs included on the NEML in secondary hospitals was 
33·7% in 2012 and 23·9% in 2013; in tertiary hospitals 
mean availability was 43·5% and 35·8%, respectively. For 
LPGs on the Shaanxi provincial medicines procurement 
list, corresponding numbers were 39·6% and 28·5% for 
secondary and 51·9% and 42·6% for tertiary hospitals, 
respectively. By contrast, mean availability of branded 
products listed on the NEML and Shaanxi provincial 
medicines procurement list showed slight numerical 
increases in these settings of between 0·3% and 0·6%. In 
private sector pharmacies, the mean availability of OBs 
on the NEML (12·4% vs 11·0%) and the provincial 
procurement list (16·3% vs 13·2%) was numerically lower 
in 2012 than in 2010. Decreases in availability of LPGs 
listed on the NEML (49·5% vs 40·1%; p<0·0001) and 
provincial procurement list (58·0% vs 47·3%; p=0·013) 
were substantially greater (ﬁ gure 2).
In the public sector, the mean availability of 26 LPG 
products on the Shaanxi provincial medicines 
procurement list was 37·9% in 2010 and 30·2% in 2012 
(p=0·064); corresponding percentages for products not 
on the list were 7·4% and 6·4% (table 2).
 For public sector procurement, the adjusted unit prices 
of all 16 available OBs had decreased by a median of 
10·9% (IQR 6·5–14·6; Wilcoxon test p=0·0004) between 
2010 and 2012, compared with a median percentage 
decrease in adjusted prices for all 29 available LPGs of 
4·9% (2·7 to –29·3; p=0·17; table 3). Similar reductions 
in adjusted procurement prices were reported across all 
three hospital levels, ranging from medians of 8·4% to 
10·5% for OB (p=0·0117 for primary, p=0·0063 for 
secondary, and p=0·0010 for tertiary hospitals), and 3·8% 
to 5·8% for LPG (all p≥0·01).
As shown in table 4, the median percentage decrease in 
public sector prices charged to patients for 16 OBs 
between 2010 and 2012 was 11·7% (IQR 4·9–15·6; 
p=0·0019), whereas the median decrease for 29 LPGs 
was 5·2% (4·2–17·3; p=0·0015). We noted signiﬁ cant 
reductions in retail prices for OBs in all three levels of 
public hospitals, with median percentage reductions in 
price ranging from 6·5% to 18·0%. However, adjusted 
prices of LPGs did not change signiﬁ cantly between 2010 
and 2012 in the three levels of hospitals, with small 
median percentage decreases of 0·2% in secondary 
hospitals and 4.9% in primary and tertiary hospitals.
In the private sector, the median percentage decrease in 
price between 2010 and 2012 for 38 LPGs was 4·7% 
Figure 2: Change in availability of 44 medicines in the private sector from 2010 to 2012
LPG=lowest-priced generic. NEML=2009 National Essential Medicines List. OB=original brand. PL=2010–12 Shaanxi provincial medicines procurement list.
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(IQR 6·3–13·2; p=0·33), whereas the median percentage 
decrease for the 16 OBs was 7·9% (4·9–13·9; p=0·0019; 
table 5).
In the 26 public sector hospitals surveyed in both years, 
only one in eight mean availability values changed 
direction when analyses were limited to these commonly 
surveyed facilities (OBs in tertiary hospitals; 20·8% vs 
19·3% for the full sample, and 20·0% vs 21·2% for 
commonly surveyed facilities). Most values were similar 
between groups (appendix). In terms of MUPs, the 
results of the sensitivity analysis were largely consistent 
with the primary analysis (appendix).
Discussion
Our ﬁ ndings partially support the hypothesis that the 
early years of NEMP implementation have been 
associated with decreased medicine prices (panel), 
especially in primary hospitals. However, more substantial 
decreases in both procurement prices and prices charged 
to patients occurred for OBs than for LPGs, despite the 
fact that generics are the primary target of the NEMP 
policy. We speculate that this ﬁ nding occurred because 
the recently centralised pharmaceutical bidding and 
distribution system improves procurement eﬃ  ciency48 
and because of cancellation of the previous 15% mark-up 
in primary hospitals.30 Additionally, after the reduction of 
the prices of medicines (which mostly targeted generic 
products) nearly 30 times since the late 1990s, the latest 
government drug price reductions for 2349  products 
mainly targeted OB products.49 However, since we 
adjusted prices for inﬂ ation, the reported price decreases 
might primarily be due to rising living standards.
Although we found lower prices for some types of 
medicines in 2012, we also noted substantial decreases in 
medicine availability, which was contrary to our 
hypothesis. Possible reasons for low public sector 
availability probably include inadequate funding, limited 
incentives for maintaining stocks, inability to forecast 
needs accurately, or ineﬃ  cient procurement systems.47 
However, the reasons probably also include unintended 
 All hospitals Tertiary hospital Secondary hospital Primary hospital
MUP 2010, 
yuan 
(n=50)
MUP 2012, 
yuan 
(n=72)
Product-speciﬁ c 
% change (%)
MUP 2010, 
yuan (n=6)
MUP 2012, 
yuan 
(n=12)
Product-speciﬁ c 
% change (%)
MUP 2010, 
yuan 
(n=20)
MUP 2012, 
yuan 
(n=24)
Product-speciﬁ c 
% change (%)
MUP 2010, 
yuan 
(n=24)
MUP 2012, 
yuan 
(n=36)
Product–speciﬁ c 
% change (%)
Lowest-price generics
All 0·270 (29) 0·133 (29) –4·9 
(–29·3 to 2·7)
0·195 (20) 0·349 (20) –3·8 
(–5·9 to 7·5)
0·378 (21) 0·216 (21) –4·9 
(–5·8 to 6·6)
0·179 (23) 0·153 (23) –5·8 
(–16·0 to 3·5)
NEML 0·135 (22) 0·103 (22) –5·6 
(–26·5 to –0·4)
0·081 (14) 0·084 (14) –4·4 
(–5·7 to 6·0)
0·110 (16) 0·108 (16) –4·9 
(–5·5 to 8·1)
0·102 (18) 0·116 (18) –5·9 
(–9·7 to 3·6)
Non-
NEML
1·005 (7) 1·154 (7) 2·7 
(–16·1 to 16·3)
1·120 (6) 1·089 (6) 0·1 
(–5·4 to 9·6)
0·610 (5) 0·772 (5) –5·0 
(–29·8 to 6·1)
0·944 (5) 0·772 (5) –2·4 
(–22·2 to –1·0)
Proc list 0·135 (22) 0·103 (22) –5·6 
(–26·5 to 1·0)
0·086 (15) 0·095 (15) –4·9 
(–6·1 to 5·3)
0·110 (16) 0·108 (16) –4·9 
(–5·5 to 8·1)
0·102 (18) 0·116 (18) –5·9 
(–9·7 to 3·6)
Non-
proc list
1·031 (7) 1·154 (7) 0·7 
(–16·1 to 7·3)
1·031 (5) 1·024 (5) 2·7 
(–2·4 to 11·9)
1·100 (5) 0·772 (5) –5·0 
(–29·8 to 6·1)
0·992 (5) 0·772 (5) –2·4 
(–22·2 to –1·0)
Acute 0·253 (12) 0·193 (12) –5·6 
(–33·9 to 8·0)
0·414 (6) 0·397 (6) –4·4 
(–5·3 to 6·0)
0·378 (7) 0·547 (7) –4·9 
(–10·0 to 15·8)
0·206 (10) 0·193 (10) –5·2 
(–14·6 to 6·8)
Chronic 0·368 (17) 0·132 (17) –4·9 
(–12·7 to 1·7)
0·195 (14) 0·349 (14) –3·1 
(–11·8 to 7·5)
0·278 (14) 0·174 (14) –4·9 
(–5·5 to 3·7)
0·179 (13) 0·153 (13) –5·8 
(–15·8 to –1·7)
Originator brands
All 3·253 (16) 2·931 (16) –10·9 
(–14·6 to –6·5)*
4·111 (14) 3·667 (14) –9·5 
(–14·3 to –6–6)*
2·446 (14) 2·564 (14) –8·4 
(–14·3 to –5·3)*
1·793 (8) 1·640 (8) –10·5 
(–14·0 to –7·4)*
NEML 2·253 (8) 2·024 (8) –12·5 
(–18·8 to –8·5)*
2·253 (8) 2·024 (8) –12·5 
(–18·8 to –8·5)*
1·400 (7) 1·196 (7) –8·6 
(–22·9 to –6·7)
0·777 (4) 0·726 (4) –8·4 
(–14·3 to –7·4)
Non-
NEML
4·259 (8) 3·746 (8) –9·1 
(–12·7 to –5·6)*
5·701 (6) 4·957 (6) –6·7 
(–11·0 to –5·9)
2·492 (7) 3·011 (7) –6·7 
(–13·0 to –5·5)
3·759 (4) 3·378 (4) –13·0 
(–14·0 to –10·6)
Proc list 2·400 (8) 2·103 (8) –13·0 
(–18·8 to –9·9)*
1·400 (7) 1·196 (7) –14·6 
(–23·0 to –9·5)
1·400 (7) 1·196 (7) –8·6 
(–22·9 to –5·0)
0·655 (3) 0·598 (3) –8·6 
(–20·0 to –6·9)
Non-
proc list
4·111 (8) 3·667 (8) –7·4 
(–12·7 to –5·6)*
5·117 (7) 4·482 (7) –6·7 
(–10·3 to –6·2)
3·106 (7) 2·852 (7) –8·2 
(–13·0 to –6·2)
3·106 (5) 2·852 (5) –12·4 
(–13·6 to –8·2)
Acute 2·900 (6) 2·643 (6) –10·4 
(–13·1 to –6·9)
2·400 (5) 2·275 (5) –9·5 
(–13·6 to –6·1)
2·400 (5) 2·275 (5) –5·2 
(–7·8 to –5·0)
0·900 (3) 0·854 (3) –5·2 
(–6·9 to –5·2)
Chronic 4·111 (10) 3·667 (10) –12·4 
(–14·6 to –6·7)*
5·117 (9) 4·482 (9) –10·3 
(–13·8 to –6·7)*
3·106 (9) 2·852 (9) –13·0 
(–14·8 to –7·8)*
3·106 (5) 2·852 (5) –13·6 
(–8·2 to –12·4)
Data are MUP (number of products found in both years) or median (IQR). MUP=median unit price. n=number of facilities participating in surveys. NEML=2009 National Essential Medicines List. Proc list=2010–12 
Shaanxi provincial medicines procurement list. *Wilcoxon signed rank test p<0·01.
Table 3: Public sector median unit procurement prices of medicines in 2010 and 2012 and median of product-speciﬁ c price changes
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consequences of the present policies. First, mandatory 
price reductions could have led to shrinking revenues 
from drug sales, which probably caused some 
manufacturers to reduce production or pull medicines 
from the market.34,50 Furthermore, because only the 
companies that oﬀ er the lowest prices can win bids, the 
new procurement process might drive some producers 
out of the market.50 Second, the ﬁ xed distribution fee (5% 
of bidding prices) is probably not adequate because of the 
geographical distance of many primary hospitals from 
urban locations. In September, 2012, 187 essential 
medicines that formerly won tenders (>10% of the total 
number) were excluded from the procurement list owing 
to deﬁ ciencies or delays in supply.51 Third, after 
implementing the zero mark-up policy on drug sales, 
primary hospitals might not have received timely or 
suﬃ  cient government ﬁ nancial support to compensate 
for the loss in drug revenue.30 This factor might 
contribute to poor availability of some low-cost essential 
medicines, which results in many patients having to 
purchase medicines in the private sector or at higher 
level hospitals.52 Fourth, the poor perceptions of 
physicians, pharmacists, and patients about the quality 
of low cost essential medicines might result in low 
demand, which contributes to speciﬁ c medicines going 
out of stock in public outlets.46 Finally, if the speciﬁ c 
strengths or dosage forms of the medicines surveyed 
were not included in the provincial medicines 
procurement list (18 of 44 surveyed medicines were not 
included), they would not be procured in Shaanxi 
Province and thus would probably be out of stock in 
primary hospitals.
The low availability of generic essential medicines 
noted over the study period was disappointing. One 
explanation for this low availability might be that health 
providers have a direct ﬁ nancial incentive to prescribe 
more expensive medications. This ﬁ nancial incentive, in 
combination with the perception that generic medicines 
are lower quality, hinders the selection and use of generic 
essential medicines.26
All hospitals Tertiary hospital Secondary hospital Primary hospital
MUP 2010, 
yuan 
(n=50)
MUP 2012, 
yuan 
(n=72)
Product-speciﬁ c 
% change (%)
MUP 2010, 
yuan (n=6)
MUP 2012, 
yuan 
(n=12)
Product-speciﬁ c 
% change (%)
MUP 2010, 
yuan 
(n=20)
MUP 2012, 
yuan 
(n=24)
Product-speciﬁ c 
% change (%)
MUP 2010, 
yuan 
(n=24)
MUP 2012, 
yuan 
(n=36)
Product-speciﬁ c 
% change (%)
Lowest-price generics
All 0·280 (29) 0·156 (29) –5·2 
(–17·3 to –4·2)*
0·225 (20) 0·412 (20) –4·9 
(–10·2 to –2·1)
0·460 (21) 0·299 (21) –0·2 
(–5·0 to 13·5)
0·280 (23) 0·170 (23) –4·9 
(–12·6 to 7·7)
NEML 0·155 (22) 0·109 (22) –4·9 
(–12·3 to –2·1)*
0·093 (14) 0·087 (14) –4·9 
(–8·6 to 0·8)
0·124 (16) 0·121 (16) 1·0 
(–4·9 to 14·0)
0·128 (18) 0·130 (18) –4·9 
(–13·1 to 2·4)
Non-
NEML
1·270 (7) 1·273 (7) –9·1 
(–19·7 to –7·1)
1·395 (6) 1·255 (6) –6·5 
(–12·9 to –4·9)
0·709 (5) 1·070 (5) –5·0 
(–15·8 to 8·3)
1·132 (5) 1·097 (5) –4·3 
(–8·9 to 17·9)
Proc list 0·155 (22) 0·109 (22) –4·9 
(–12·2 to –0·8)
0·099 (15) 0·094 (15) –4·9 
(–7·4 to –0·6)
0·124 (16) 0·121 (16) 1·0 
(–4·9 to 16·4)
0·128 (18) 0·130 (18) –4·9 
(–13·1 to 2·4)
Non-
proc list
1·400 (7) 1·273 (7) –10·4 
(–19·7 to –8·5)
1·391 (5) 1·179 (5) –8·0 
(–14·6 to –4·9)
1·270 (5) 1·070 (5) –5·0 
(–15·8 to 7·5)
1·146 (5) 1·097 (5) –4·3 
(–8·9 to 15·5)
Acute 0·279 (12) 0·211 (12) –7·5 
(–18·7 to –2·1)
0·476 (6) 0·530 (6) –4·2 
(–10·2 to 5·0)
0·460 (7) 0·753 (7) 13·5 
(–0·2 to 29·9)
0·223 (10) 0·211 (10) –6·4 
(–48·1 to 0·1)
Chronic 0·466 (17) 0·153 (17) –5·2 
(–9·7 to –4·9)*
0·225 (14) 0·412 (14) –4·9 
(–9·5 to –4·9)
0·321 (14) 0·232 (14) –4·9 
(–16·4 to 3·5)
0·393 (13) 0·170 (13) –4·5 
(–6·9 to 16·7)
Originator brands
All 4·250 (16) 3·282 (16) –11·7 
(–15·6 to –4·9)*
4·729 (14) 4·285 (14) –6·5 
(–12·0 to –4·9)*
2·910 (14) 2·778 (14) –8·5 
(–13·1 to –5·7)*
2·066 (8) 1·703 (8) –18·0 
(–25·5 to –12·8)*
NEML 3·105 (8) 2·392 (8) –14·2 
(–27·2 to –7·3)*
2·591 (8) 2·392 (8) –9·8 
(–17·9 to –4·9)
1·624 (7) 1·483 (7) –8·7 
(–22·4 to –8·2)
0·953 (4) 0·846 (4) –21·8 
(–33·7 to –12·4)
Non-
NEML
4·893 (8) 4·172 (8) –8·5 
(–12·4 to –4·9)
6·557 (6) 5·793 (6) –5·0 
(–9·7 to –4·9)
2·969 (7) 2·931 (7) –7·9 
(–11·7 to –4·9)
4·296 (4) 3·740 (4) –18·0 
(–20·4 to –15·4)
Proc list 2·755 (8) 2·278 (8) –14·2 
(–21·7 to –7·3)*
1·610 (7) 1·388 (7) –11·6 
(–22·1 to –6·5)
1·624 (7) 1·483 (7) –8·4 
(–19·5 to –6·5)
0·800 (3) 0·694 (3) –13·3 
(–21·8 to –11·5)
Non-
proc list
5·243 (8) 4·285 (8) –8·5 
(–12·4 to –4·9)
5·886 (7) 5·175 (7) –4·9 
(–8·1 to –4·9)
3·943 (7) 3·376 (7) –11·3 
(–12·8 to –6·4)
5·821 (5) 3·572 (5) –19·2 
(–23·8 to –16·8)
Acute 3·340 (6) 2·896 (6) –8·1 
(–16·7 to –5·3)
2·760 (5) 2·624 (5) –6·5 
(–10·7 to –4·9)
2·850 (5) 2·624 (5) –8·0 
(–8·3 to –5·6)
1·105 (3) 0·998 (3) –13·3 
(–15·0 to –11·5)
Chronic 5·243 (10) 4·285 (10) –12·1 
(–13·8 to –4·9)
5·886 (9) 5·175 (9) –8·1 
(–12,5 to –4·9)
3·943 (9) 3·376 (9) –11·7 
(–13·7 to –7·8)*
5·821 (5) 3·572 (5) –23·8 
(–30·3 to –19·2)
Data are MUP (number of products found in both years) or median (IQR). MUP=median unit price. n=number of facilities participating in both su rveys. NEML=2009 National Essential Medicines List. Proc list=2010–12 
Shaanxi provincial medicines procurement list. *Wilcoxon signed rank test p<0·01.
Table 4: Median unit prices charged to patients for medicines in all public sector hospitals
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Mean availability of surveyed medicines was 
numerically higher in private pharmacies than in the 
public sector. However, the availability of medicines in 
the private sector was still insuﬃ  cient. These ﬁ ndings 
are similar to those from surveys undertaken in other 
countries.47,53,54 In the private sector, generic medicines 
typically cost more than in the public sector and are often 
not reimbursed under the medical insurance scheme. 
Furthermore, shortages of lower cost generic essential 
medicines might force patients to buy more expensive 
brand-name drugs. These factors can increase the 
economic burden for patients. Policies are needed to 
ensure that ﬁ rst-line generic medicines are available and 
preferentially prescribed and dispensed in both sectors. 
In 2012, the availability of 15 products that are commonly 
surveyed in WHO/HAI surveys was lower in all sectors 
for all product types than the availability in 36 countries 
at all income levels.47
Our study has several important limitations. First, the 
validated WHO/HAI methodology has been used in 
many other national and regional price and availability 
surveys.55,56 However, availability and prices are measured 
for a limited number of speciﬁ c products to facilitate 
comparisons across countries;35,57 therapeutic alternatives 
or alternate dosage forms are not accounted for in the 
survey methodology. Thus, some facilities might have 
had therapeutically comparable products in stock, but 
with diﬀ erent strengths or dosage forms. Although we 
included several supplementary medicines, the 
medicines surveyed might not represent the entire 
market. Second, the limited number of health facilities 
and low availability might make the MUPs less robust 
than hoped owing to the small numbers of prices 
obtained, especially for less frequently found products. 
Third, sample facilities were not consistent in the two 
surveys, which constrained our ability to assess changes 
between 2010 and 2012. However, our sensitivity analysis 
in the subset of common facilities mostly conﬁ rms the 
results.
The main limitation of our analyses lies in the fact that 
we have data at only two timepoints after the 2009 health-
care reforms, and no comparable data before the reform. 
To validly assess the eﬀ ects of the 2009 reform and future 
policy adaptations, longitudinal data including many 
timepoints before and after intervention would be 
needed.58 We used publicly reported data to account for 
price inﬂ ation from 2010 to 2012.44 Changes in prices 
might be misrepresented, although they are generally 
consistent with other data on increases in living standards 
during this period.44,59
Based on our ﬁ ndings, research is needed into the 
eﬀ ects of policy interventions to improve the availability 
and reduce the price of essential medicines in Shaanxi 
Province. This research might involve adjusting 
provincial essential medicines and procurement lists to 
match standard treatment guidelines for the most 
prevalent disorders. Interventions could also aim to 
target ineﬃ  ciencies in the distribution chain, improve 
transparency and eﬃ  ciency of the bidding system, and 
MUP 2010, 
yuan 
(n=36)
MUP 2012, 
yuan 
(n=72)
Product-speciﬁ c 
% change 
(median [IQR])
Lowest-price generics
All (38) 0·416 0·459 –4·7 (–13·2 to 6·3)
NEML (27) 0·150 0·166 –1·5 (–10·4 to 3·7)
Non-NEML(11) 1·315 1·223 –7·4 (–21·8 to 12·1)
Proc list (25) 0·158 0·178 –1·4 (–9·6 to 6·5)
Non-proc list (13) 1·200 0·970 –8·3 (–20·8 to 5·9)
Acute (17) 0·453 0·442 –1·4 (–12·2 to 13·7)
Chronic (21) 0·380 0·540 –6·2 (–16·0 to 3·2)
Originator brands
All (16) 3·326 2·424 –7·9 (–13·9 to –4·9)*
NEML (7) 1·388 1·298 –7·5 (–14·0 to –5·3)
Non-NEML (9) 4·214 2·472 –8·3 (–11·3 to –4·9)
Proc list (7) 1·388 1·298 –6·5 (–10·8 to –2·7)
Non-proc list (9) 4·214 2·472 –11·2 (–13·9 to –6·2)*
Acute (5) 2·500 2·377 –4·6 (–6·9 to –1·9)
Chronic (11) 4·214 2·472 –11·2 (–21·9 to –6·9)*
Numbers in parentheses are number of products found in both years. n=number 
of facilities participating in surveys. NEML=2009 National Essential Medicines 
List. Proc list=2010–12 Shaanxi provincial medicines procurement list. *Wilcoxon 
signed rank test p<0·01.
Table 5: Median unit price for medicines in private sector pharmacies
Panel: Research into context
Systematic review
We searched PubMed and Google Scholar for published articles and reports with the 
terms “essential medicine”, “price”, “availability”, “aﬀ ordability”, “pharmaceutical policy”, 
and “healthcare reform”. We identiﬁ ed three previous studies36–38 in which the 2003 
Edition of WHO and Health Action International methodology was used to measure 
medicine prices, availability, and aﬀ ordability in eastern and central China. Results from 
two surveys33,46 showed unsatisfactory manufacturing, supply, and prescribing status in 
Shandong, Gansu, and Hubei provinces. Results from a secondary analysis47 of 36 
developing and middle-income countries revealed there was much room for increasing 
availability, reducing prices, and improving aﬀ ordability. The Chinese Essential Medicine 
Policy was analysed in ﬁ ve descriptive studies.8,17,24,31,32 Findings from two reviews25,30 and 
three reports26–28 that tracked China’s health-care reform emphasised the necessity of 
independent, outcome-based monitoring and assessment by a third party. These studies 
attempted to investigate the eﬀ ects of the National Essential Medicine Policy (NEMP) 
but were limited to data before 2009, non-independent authority reports, or qualitative 
designs. We aimed to study the short-term patterns of medicine availability and prices in 
Shaanxi Province during the early years of NEMP implementation by undertaking two 
cross-sectional surveys.39,40
Interpretation
This study provides up-to-date evidence of major diﬀ erences in access to aﬀ ordable 
medicines at two timepoints after health-care reform in underdeveloped western China. 
Although the prices charged to patients have decreased, probably owing to rising living 
standards, we identiﬁ ed concerning decreases in availability of many essential medicines in 
both public and private outlets. There is a need to establish a routine information system to 
monitor the eﬀ ects of further implementation of the Chinese Essential Medicine Policy.
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Shaanxi Province. http://www.sxfda.gov.cn/CL0481/3759.html (in 
Chinese; accessed Sept 3, 2013).
23 The Shaanxi Provincial Government. The implementation of 
essential medicine policy in Shaanxi Province. http://www.
shaanxi.gov.cn/0/1/6/17/953/958/79488.htm (in Chinese; accessed 
Dec 25, 2012).
24 Guan X, Liang H, Xue Y, Shi L. An analysis of China’s National 
Essential Medicines Policy. J Public Health Policy 2011; 3: 305–19.
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provide better information about product quality. 
Linking price to quality might stimulate manufacturers 
to expand production of high-quality low-cost essential 
medicines. Studies should examine the eﬀ ects of 
increasing government subsidies or medical service 
fees for primary hospitals to compensate for reduced 
revenue due to the zero mark-up policy. Additional 
research is needed on the eﬀ ects of ﬁ nancial incentives 
by health insurance organisations to encourage 
appropriate prescribing and use of essential medicines. 
In the long run, only complementary policies 
implemented at all levels will achieve the NEMP goal of 
equitable, aﬀ ordable, and sustainable access to quality 
essential medicines.
In summary, the early years of the implementation of 
the NEMP in one province in western China have been 
characterised by relative reductions in medicine prices 
but lower medicine availability in the public and private 
sectors, especially in primary hospitals. Future policies 
need to target medicine availability as well as price. There 
is a need for a system that uses routine data, perhaps 
combining data from hospitals and insurance systems, 
to monitor standardised indicators of availability, price, 
and use of medicines.
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